29th Feb 2016 10:09
LONDON (Alliance News) - Verseon Corp said Monday that it presented preclinical data on its thrombin inhibitors as a potential treatment for arterial thrombotic disorders at the 3rd International Conference on Heart & Brain in Paris last week.
This data demonstrated the effectiveness of the thrombin inhibitors as a treatment with a lower bleeding risk than current anticoagulants, Verseon said, and built on other preclinical data it presented at the Biotech Showcase 2016 in San Francisco.
"We are very encouraged by the recent positive preclinical results for our novel class of oral anticoagulants," said Chief Executive Officer and Co-Founder Adityo Prakash.
Shares in Verseon Corp were down 2.1% at 166.00 pence Monday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.